David Waltz

7.0k total citations · 3 hit papers
47 papers, 5.2k citations indexed

About

David Waltz is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, David Waltz has authored 47 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 6 papers in Physiology and 6 papers in Immunology and Allergy. Recurrent topics in David Waltz's work include Cystic Fibrosis Research Advances (34 papers), Neonatal Respiratory Health Research (16 papers) and Tracheal and airway disorders (15 papers). David Waltz is often cited by papers focused on Cystic Fibrosis Research Advances (34 papers), Neonatal Respiratory Health Research (16 papers) and Tracheal and airway disorders (15 papers). David Waltz collaborates with scholars based in United States, Australia and United Kingdom. David Waltz's co-authors include Harold A. Chapman, Ying Wei, Michael W. Konstan, Gautham Marigowda, Bonnie W. Ramsey, Xiaohong Huang, Michael Boyle, Susanna A. McColley, Steven M. Rowe and Armin Ernst and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

David Waltz

47 papers receiving 5.1k citations

Hit Papers

Lumacaftor–Ivacaftor in Pati... 1994 2026 2004 2015 2015 1994 2014 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR
    2015 1.2k citations Claire Wainwright, J.S. Elborn et al. New England Journal of Medicine profile →
  2. Identification of the urokinase receptor as an adhesion receptor for vitronectin.
    1994 517 citations Ying Wei, David Waltz et al. profile →
  3. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial
    2014 336 citations Michael Boyle, Scott C. Bell et al. The Lancet Respiratory Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Waltz United States 28 3.5k 986 963 566 537 47 5.2k
Stefan Burdach Germany 44 2.1k 0.6× 763 0.8× 2.1k 2.2× 222 0.4× 1.1k 2.1× 210 7.3k
Victoria A. Ploplis United States 37 696 0.2× 1.6k 1.6× 1.4k 1.4× 366 0.6× 1.4k 2.5× 143 5.1k
Bruce Robinson Australia 49 4.0k 1.2× 463 0.5× 1.4k 1.5× 226 0.4× 101 0.2× 176 9.7k
Lise Halbwachs‐Mecarelli France 33 943 0.3× 230 0.2× 1.2k 1.2× 686 1.2× 914 1.7× 75 5.1k
Henrik Sengeløv Denmark 36 616 0.2× 473 0.5× 1.9k 2.0× 647 1.1× 1.4k 2.7× 149 6.2k
Sinuhe Hahn Switzerland 47 486 0.1× 827 0.8× 2.0k 2.0× 206 0.4× 452 0.8× 162 7.1k
Clinton S. Robbins Canada 31 975 0.3× 335 0.3× 1.4k 1.5× 253 0.4× 168 0.3× 49 5.6k
D Émilie France 38 1.3k 0.4× 213 0.2× 579 0.6× 195 0.3× 264 0.5× 92 5.5k
Christoph Hess Switzerland 37 633 0.2× 689 0.7× 1.6k 1.7× 123 0.2× 244 0.5× 95 5.5k
Ioannis Mitroulis Greece 36 694 0.2× 219 0.2× 1.7k 1.8× 324 0.6× 466 0.9× 81 5.1k

Countries citing papers authored by David Waltz

Since Specialization
Citations

This map shows the geographic impact of David Waltz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Waltz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Waltz more than expected).

Fields of papers citing papers by David Waltz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Waltz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Waltz. The network helps show where David Waltz may publish in the future.

Co-authorship network of co-authors of David Waltz

This figure shows the co-authorship network connecting the top 25 collaborators of David Waltz. A scholar is included among the top collaborators of David Waltz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Waltz. David Waltz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainwright, Claire, Susanna A. McColley, Paul McNally, et al.. (2025). Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. American Journal of Respiratory and Critical Care Medicine. 211(10). 1915–1925. 1 indexed citations
2.
McNamara, John, Susanna A. McColley, Gautham Marigowda, et al.. (2019). Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2–5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. The Lancet Respiratory Medicine. 7(4). 325–335. 102 indexed citations
3.
Taylor‐Cousar, Jennifer L., Marcus Mall, Bonnie W. Ramsey, et al.. (2019). Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or twoF508delalleles. ERJ Open Research. 5(2). 82–2019. 79 indexed citations
4.
McColley, Susanna A., Michael W. Konstan, Bonnie W. Ramsey, et al.. (2018). Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV1. Journal of Cystic Fibrosis. 18(1). 94–101. 33 indexed citations
5.
Milla, Carlos, Félix Ratjen, Gautham Marigowda, et al.. (2017). Lumacaftor/Ivacaftor in Patients Aged 6–11 Years with Cystic Fibrosis and Homozygous for F508del-CFTR. American Journal of Respiratory and Critical Care Medicine. 195(7). 912–920. 119 indexed citations
6.
Elborn, J.S., Bonnie W. Ramsey, Michael Boyle, et al.. (2016). Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis. The Lancet Respiratory Medicine. 4(8). 617–626. 118 indexed citations
7.
McColley, Susanna A., Michael W. Konstan, Bonnie W. Ramsey, et al.. (2015). Association between changes in percent predicted fev1 and incidence of pulmonary exacerbations, including those requiring hospitalization and/or iv antibiotics, in patients with CF treated with lumacaftor in combination with ivacaftor. Pediatric Pulmonology. 50. 282–282. 5 indexed citations
8.
Konstan, Michael W., Bonnie W. Ramsey, J.S. Elborn, et al.. (2015). Safety and efficacy of treatment with Lumacaftor in combination with Ivacaftor in patients with Cf homozygous for F508Del-Cftr. Pediatric Pulmonology. 50. 269–270. 1 indexed citations
9.
Wainwright, Claire, J.S. Elborn, Bonnie W. Ramsey, et al.. (2015). Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR. New England Journal of Medicine. 373(3). 220–231. 1207 indexed citations breakdown →
10.
Rowe, Steven M., Susanna A. McColley, E. Rietschel, et al.. (2014). EFFECT OF 8 WEEKS OF LUMACAFTOR IN COMBINATION WITH IVACAFTOR IN PATIENTS WITH CF AND HETEROZYGOUS FOR THE F508DEL-CFTR MUTATION. Pediatric Pulmonology. 49. 306–306. 2 indexed citations
11.
Tiddens, Harm A.W.M., Michael Puderbach, José G. Venegas, et al.. (2014). Novel outcome measures for clinical trials in cystic fibrosis. Pediatric Pulmonology. 50(3). 302–315. 31 indexed citations
12.
Rowe, Steven M., Heather Hathorne, Didier Renard, et al.. (2013). Reduced Sodium Transport With Nasal Administration of the Prostasin Inhibitor Camostat in Subjects With Cystic Fibrosis. CHEST Journal. 144(1). 200–207. 26 indexed citations
13.
Uluer, Ahmet, et al.. (2012). Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis. Journal of Cystic Fibrosis. 12(1). 54–59. 10 indexed citations
14.
Lee, Edward Y., et al.. (2007). MDCT assessment of tracheomalacia in symptomatic infants with mediastinal aortic vascular anomalies: preliminary technical experience. Pediatric Radiology. 38(1). 82–88. 32 indexed citations
15.
Waltz, David, Mark M. Boucek, Leah B. Edwards, et al.. (2006). Registry of the International Society for Heart and Lung Transplantation: Ninth Official Pediatric Lung and Heart–Lung Transplantation Report—2006. The Journal of Heart and Lung Transplantation. 25(8). 904–911. 32 indexed citations
16.
Carden, Kelly A., Philip M. Boiselle, David Waltz, & Armin Ernst. (2005). Tracheomalacia and Tracheobronchomalacia in Children and Adults. CHEST Journal. 127(3). 984–1005. 452 indexed citations
17.
Moss, Richard B., David M. Rodman, L. Terry Spencer, et al.. (2004). Repeated Adeno-Associated Virus Serotype 2 Aerosol-Mediated Cystic Fibrosis Transmembrane Regulator Gene Transfer to the Lungs of Patients With Cystic Fibrosis. CHEST Journal. 125(2). 509–521. 292 indexed citations
18.
Gibson, Ronald L., Julia Emerson, Sharon McNamara, et al.. (2003). Significant Microbiological Effect of Inhaled Tobramycin in Young Children with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 167(6). 841–849. 243 indexed citations
19.
Slattery, Dubhfeasa, et al.. (2001). Bronchoscopically administered recombinant human DNase for lobar atelectasis in cystic fibrosis*. Pediatric Pulmonology. 31(5). 383–388. 29 indexed citations
20.
Waltz, David, et al.. (1997). Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.. Journal of Clinical Investigation. 100(1). 58–67. 241 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stefan Burdach Breakdown of academic impact, for papers by Victoria A. Ploplis Breakdown of academic impact, for papers by Bruce Robinson Breakdown of academic impact, for papers by Lise Halbwachs‐Mecarelli Breakdown of academic impact, for papers by Henrik Sengeløv Breakdown of academic impact, for papers by Sinuhe Hahn Breakdown of academic impact, for papers by Clinton S. Robbins Breakdown of academic impact, for papers by D Émilie Breakdown of academic impact, for papers by Christoph Hess Breakdown of academic impact, for papers by Ioannis Mitroulis
Rankless by CCL
2026